Gregory Renza: Got it. Thanks, Steve. Appreciate it.
Operator: Thank you. One moment for our next question. Our next question comes from the line of Jeff Hung from Morgan Stanley.
Jeff Hung: Thanks for taking my question. Can you share with us some of the current — recent feedback you have been hearing from your conversations with payers of trofinetide, is there anything that you found surprising? Thanks.
Steve Davis: Yeah. Thanks much for the question. Brendan, do you want to take that?
Brendan Teehan: Sure. Yeah. Thanks for the question. Just in context, we have had discussions with payers really since we acquired the program dating back over a year at this point. But even more recent conversations, I would say that, payers have very logical questions that we are able to address. The first is many payers simply don’t know what Rett syndrome is. We have to describe this as a devastating disease, the fact that it requires a round-the-clock support and dimensionalize it for them from the outset. They are very well aware that trofinetide would be the only FDA approved drug for treating the core symptoms of Rett in that it is different than some of the individual symptomatic types of medications that may have proceeded it.
They are aware of now from our education trofinetide, that positive benefit risk profile and understand that this is a rare disease space with a pricing model for products like this that they have come to expect and that this is a very rare and difficult population. So, given that, we feel confident that we are going to be able to ensure access to patients — to appropriate patients and their families if we are lucky enough to have an approval in the near-term
Jeff Hung: Thank you.
Operator: Thank you. One moment for our next question. Our next question comes from the line of Paul Matteis from Stifel.
Unidentified Analyst: Hello. Thanks for taking my question. This is Catherine on for Paul. Just on trofinetide on the regulatory side. What do you see as the greatest risk to approval at this point if any and then on the launch, how are you thinking about the cadence post approval and how soon after you can expect to start treating patients? Thanks.
Steve Davis: Yeah. Thanks much for the — for two questions. Brendan, do you want to take the second question first?
Brendan Teehan: Sure. Thanks for the question. As you would expect, we are doing everything that you would expect of a company getting ready to launch a first-in-class product in a rare disease and we will be ready to go pretty quickly after approval. There are really just a few things from a logistical perspective that takes some time. One is the finalization of a label, obviously, because it has lots of implications about product drug availability, also training our field force to make sure that they are 100% prepared to support the physicians that want to prescribe and the families that want to get started. But other than those simple logistics, we see no other reasons for delay and we know that the community is waiting.
